Navigation Links
Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth Through 2018
Date:9/8/2010

BURLINGTON, Mass., Sept. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increasing use of U.S. regulatory-approved agents -- Pfizer's Lyrica (pregabalin), Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeristar (duloxetine) and Forest Laboratories' Savella (milnacipran) -- will drive 4.2 percent annual growth in the fibromyalgia drug market from 2009 to 2018. However, owing to the generic entry of sales-leading pregabalin, the market will decline sharply from $1.8 billion in 2018 to only $1.4 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Fibromyalgia reveal that an expanding drug-treated population, resulting from increasing diagnosis rates, will fuel annual market growth over the next several years in the world's major pharmaceutical markets. While the United States will account for more than two-thirds of major-market fibromyalgia drug sales in 2019, market expansion in Europe and Japan will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder.

The findings also reveal that duloxetine is now in close competition with pregabalin for market-leading status in the United States.

"Although pregabalin was the U.S. patient- and market-share leader in 2009, patient share of duloxetine grew significantly last year," said Decision Resources Analyst Andrea Buurma. "Sales of duloxetine are not projected to surpass pregabalin sales during our forecast period, owing in large part to market entry of generic duloxetine in the United States in 2013; however, we do expect duloxetine to supplant pregabalin as the U.S. patient-share leader by 2015."

The Pharmacor 2010 findings also reveal that, in light of the recent recommendation by an FDA advisory committee against the approval of sodium oxybate (Jazz Pharmaceuticals/UCB's JZP-6) for fibromyalgia, Decision Resources forecasts that it is unlikely the FDA will approve this agent for the indication. However, if the FDA issues a complete response letter and Jazz Pharmaceuticals is ultimately able to address the concerns voiced by the panel -- such as additional safety and efficacy data and a stricter Risk Evaluation and Mitigation Strategy -- sodium oxybate could have the potential to launch as a fibromyalgia therapy by late 2013.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Increasing Potential for RIS-driven PACS Modules in Europe, Finds Frost & Sullivan
2. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
3. GeneGo Releases Content and Tools From Industry-FDA Driven MetaTox Partnership Via ToxHunter(TM)
4. Energetiq Introduces Laser-Driven Light Sources for Biophysical Applications
5. The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018
6. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
7. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
8. Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge
9. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
10. Recession Leads to Sales Decline and Loss for Allied Healthcare Products in Fiscal 2010
11. Kewaunee Scientific Reports Sales and Earnings for First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... de 2016  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela ... para a doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of ... , , ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Cellairis is a worldwide mobile device ... iPhone , iPad and Samsung Galaxy devices with premium parts and ... order to maximize convenience and accessibility for customers. While customers do their shopping, Cellairis ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... solutions, proudly announced today that a new solution for Emergency Departments (ED) has ... the tight space in Emergency Department examination rooms, and with a simplified pallet ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida ... Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This ... Only a few hospitals and facilities have earned this distinction. This is the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
Breaking Medicine News(10 mins):